Properties (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Perrigo_Company
|
| gptkbp:decommissioningDate |
NASDAQ_in_2014
|
| gptkbp:develops |
formulations for pharmaceuticals
|
| gptkbp:founded |
1990
|
| gptkbp:founder |
gptkb:K._Michael_McGhan
|
| gptkbp:has_a_focus_on |
research and development
quality assurance clinical trials manufacturing processes mergers and acquisitions metabolic disorders oncology personalized medicine product development rare diseases supply chain management autoimmune diseases chronic diseases licensing agreements market access business development strategic partnerships vaccines central nervous system disorders cardiovascular diseases biologics therapeutics infectious diseases pain management pharmacovigilance women's health health economics respiratory diseases gastrointestinal diseases diagnostics neurological diseases regulatory affairs pediatric health dermatological conditions improving drug efficacy reducing side effects geriatric_health |
| gptkbp:has_expertise_in |
biotechnology
nanotechnology polymer science |
| gptkbp:has_partnerships_with |
various pharmaceutical companies
|
| gptkbp:headquarters |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Elan Drug Technologies
|
| gptkbp:offers |
injectable drug delivery systems
oral drug delivery systems transdermal drug delivery systems |
| gptkbp:produces |
multiple patented technologies
|
| gptkbp:receives |
FDA_approvals
|
| gptkbp:specializesIn |
drug delivery technologies
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:subsidiary |
gptkb:Elan_Pharmaceuticals
|